ObsEva SA (OBSV): Price and Financial Metrics
GET POWR RATINGS... FREE!
OBSV Stock Price Chart Interactive Chart >
OBSV Price/Volume Stats
| Current price | $3.15 | 52-week high | $5.55 |
| Prev. close | $3.16 | 52-week low | $1.86 |
| Day low | $3.09 | Volume | 565,200 |
| Day high | $3.23 | Avg. volume | 2,981,525 |
| 50-day MA | $2.81 | Dividend yield | N/A |
| 200-day MA | $3.01 | Market Cap | 181.29M |
ObsEva SA (OBSV) Company Bio
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. The company was founded in 2012 and is based in Switzerland.
Latest OBSV News From Around the Web
Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.
ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids(RTTNews) - ObsEva SA (OBSV) said Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options. |
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids - |
ObsEva SA: ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive dat |
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine FibroidsObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids. |
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P |
OBSV Price Returns
| 1-mo | 10.14% |
| 3-mo | 3.28% |
| 6-mo | 3.96% |
| 1-year | 28.05% |
| 3-year | -82.57% |
| 5-year | N/A |
| YTD | 51.44% |
| 2020 | -45.55% |
| 2019 | -69.83% |
| 2018 | 29.71% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...